5Simon L S,Lanza F L,Lipsky P E,et al. Preliminary stuely of safety and efficacy of Se-58635 ,a norel eyelooxygenase 2-inhibitor :efficacy and treumatoid arthtitis, and studies of gastrointestinal and platelet effeets[J]. Arthritis Rheum, 1998, 41 (9) 1591-1602.
6Furst D E, The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases[J]. Br J Rheumatol, 1997, 36(1) : 1196-1204.
7Le Thi Huong D, Papo, Piette J C, et al. Monthly intravenous pulse eyelophosphamide therapy in Wegener's granulomatosis [J]. Clin Ex Rheumatol, 1996,14:9-16.
8Calabrese L H. Molecular differencesln anttcytolcine therapies [J]. Clin Exp Rheumatol, 2003,21 : 241-248.
9Furst D E, Breedveld F C, Kalden J R, et al. Updated consensus statement onbiolgical agents, specifically tumour necrosis factor-α(INF-α) bloclcmg agents and interlenkin-1 receptor antagonist(L-Ira), for the treatment of theumatic diseases[J] . Ann Rheum Dis,2005,64(4):2-14.
